Radiation oncologist · Kyoto University Hospital · Japan (JP) · Oncology
Data minimisation
Cadence target for Tier 3: 1 per year (assumption)
3 of 1 expected engagements
No insights captured from engagements with this stakeholder.
All engagements including drafts, newest first
| Date | Type | Format | MSL | Product | Topics | Insights | Flags | Status | |
|---|---|---|---|---|---|---|---|---|---|
| 17 Aug 2026 | Scientific exchange | In person | James Whitfield | Vantrexa | Sequencing after progression | 0 | — | Reviewed | ENG-0018 |
| 07 Jun 2026 | Scientific exchange | In person | James Whitfield | Vantrexa | PD-L1 testing turnaroundChemotherapy-free first line | 0 | — | Reviewed | ENG-0014 |
| 03 May 2026 | Scientific exchange | Virtual | James Whitfield | Vantrexa | Sequencing after progressionElderly / ECOG 2 patients+1 | 0 | MI request | Reviewed | ENG-0009 |
17 Aug 2026
Sequencing after progression
07 Jun 2026
PD-L1 testing turnaround, Chemotherapy-free first line
03 May 2026
Sequencing after progression, Elderly / ECOG 2 patients, Chemotherapy-free first line
Kyoto University Hospital
Pathologist
Pathologist
Radiation oncologist
General neurologist
General neurologist
Primary care physician
General neurologist